Greenwich Lifesciences Inc Quick Ratio (GLSI) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Greenwich Lifesciences Inc   (NASDAQ: GLSI)

Greenwich Lifesciences Inc 's Quick Ratio

GLSI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.5 below Greenwich Lifesciences Inc average.

Within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Quick Ratio than Greenwich Lifesciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1246 to 1638.

Explain Quick Ratio?
How much Cash & cash equivalents GLSI´s has?
What are GLSI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLSI Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 251.4 % 302.86 % 54.68 % 92.55 % 24.58 %
Y / Y Cash & cash equivalent Change 184.03 % 282.02 % 50.98 % -34.61 % -56.75 %
Quick Ratio MRQ 1.5 2.3 1.2 2.35 1.85
GLSI's Total Ranking # 1638 # 1246 # 942 # 966 #
Seq. Current Liabilities Change 29.85 % -11.45 % 217.57 % -3.77 % 48.87 %
Seq. Cash & cash equivalent Change -15.51 % 70.05 % 62.28 % 21.82 % 13.64 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 321
Healthcare Sector # 565
Overall Market # 1638


Quick Ratio Statistics
High Average Low
81.85 27.74 0.01
(Mar 31 2022)   (Dec 31 2019)




Financial Statements
Greenwich Lifesciences Inc 's Current Liabilities $ 6 Millions Visit GLSI's Balance sheet
Greenwich Lifesciences Inc 's Cash & cash equivalent $ 9 Millions Visit GLSI's Balance sheet
Source of GLSI's Sales Visit GLSI's Sales by Geography


Cumulative Greenwich Lifesciences Inc 's Quick Ratio

GLSI's Quick Ratio for the trailling 12 Months

GLSI Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 146.88 % 95.56 % 62.14 % 153.74 % 177.72 %
Y / Y Cash & cash equivalent TTM Growth 85.99 % 18.74 % -29.96 % -46.07 % -45.3 %
Quick Ratio TTM 1.7 1.81 1.65 1.77 2.26
Total Ranking TTM # 3937 # 3901 # 3180 # 2659 #
Seq. Current Liabilities TTM Growth 32.55 % 35.75 % 23.44 % 11.15 % 5 %
Seq. Cash & cash equivalent TTM Growth 24.35 % 48.9 % 15.14 % -12.76 % -20.61 %

Quick ratio ranking by company, industry and sector >> Back to GLSI Financial Strength Comparisons >> Go to Compare GLSI Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $5.92 millions, cumulative Quick Ratio decreased to 1.7 below the Greenwich Lifesciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 434 other companies have achieved higher Quick Ratio than Greenwich Lifesciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3901 to 3937.

Explain Quick Ratio?
How much Cash & cash equivalents GLSI´s has?
What are GLSI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 435
Healthcare Sector # 890
Within the Market # 3937


trailing twelve months Quick Ratio Statistics
High Average Low
72.96 29.75 1.5
(Sep 30 2022)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Gyre Therapeutics Inc   4.12 $ 86.289  Millions$ 20.957  Millions
Seaport Therapeutics Inc   4.11 $ 64.423  Millions$ 15.674  Millions
Prelude Therapeutics Inc  3.99 $ 151.757  Millions$ 38.042  Millions
Alx Oncology Holdings Inc  3.97 $ 22.753  Millions$ 5.731  Millions
Actinium Pharmaceuticals Inc  3.94 $ 36.473  Millions$ 9.260  Millions
Veru Inc   3.88 $ 23.880  Millions$ 6.156  Millions
Gain Therapeutics inc  3.81 $ 13.084  Millions$ 3.434  Millions
Bolt Biotherapeutics Inc   3.79 $ 29.823  Millions$ 7.867  Millions
Acurx Pharmaceuticals inc   3.72 $ 10.656  Millions$ 2.865  Millions
Maplight Therapeutics Inc   3.71 $ 71.633  Millions$ 19.294  Millions
Aptevo Therapeutics Inc   3.47 $ 17.997  Millions$ 5.188  Millions
Ataibeckley Inc   3.43 $ 168.807  Millions$ 49.221  Millions
Dogwood Therapeutics inc   3.40 $ 9.628  Millions$ 2.831  Millions
Tvardi Therapeutics Inc   3.39 $ 30.865  Millions$ 9.113  Millions
Biomea Fusion Inc   3.32 $ 34.824  Millions$ 10.483  Millions
Abeona Therapeutics Inc   3.32 $ 146.826  Millions$ 44.233  Millions
Foghorn Therapeutics Inc   3.31 $ 167.582  Millions$ 50.579  Millions
Cingulate Inc   3.29 $ 28.403  Millions$ 8.631  Millions
Unicycive Therapeutics Inc  3.28 $ 61.425  Millions$ 18.704  Millions
Harmony Biosciences Holdings inc   3.17 $ 667.791  Millions$ 210.812  Millions
Pulmatrix Inc   3.15 $ 2.168  Millions$ 0.689  Millions
Nextcure Inc   3.13 $ 20.088  Millions$ 6.413  Millions
Dianthus Therapeutics Inc   3.13 $ 107.611  Millions$ 34.389  Millions
Tg Therapeutics Inc   3.02 $ 811.665  Millions$ 268.493  Millions
Dermata Therapeutics Inc   3.02 $ 4.413  Millions$ 1.462  Millions
Xilio Therapeutics Inc   2.99 $ 136.040  Millions$ 45.487  Millions
Cadrenal Therapeutics Inc  2.99 $ 4.476  Millions$ 1.497  Millions
Zevra Therapeutics Inc   2.99 $ 145.321  Millions$ 48.632  Millions
Inhibitor Therapeutics Inc   2.95 $ 0.516  Millions$ 0.175  Millions
Annovis Bio Inc   2.95 $ 18.736  Millions$ 6.359  Millions

Date modified: 2026-09-26T07:40:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.